Genetic risk factors for behavioral adverse reactions in epileptic patients taking levetiracetam

Levetiracetam (LEV) is an effective antiepileptic drug. Nevertheless, when the drug is used, its behavioral adverse drug reactions (ADRs), such as aggressivity, irritability, hyperexcitability, and anxiety, occur in almost 30% of cases. Recent studies show that personality traits can predispose to LEV-induced ARs.

Objective: to establish genetic risk factors for behavioral ADRs in epileptic patients taking LEV.
Patients and methods. Single nucleotide variants (SNVs) were chosen according to their importance for the development of impulsivity and aggressivity. At Stage 1, the dose-dependent effect of LEV, which was responsible for behavioral ADRs, was studied in 179 epileptic patients taking this drug, who were divided into four groups according to age and the presence of ADRs. Molecular genetic testing of SNVs DRD2 rs1800497 (DRD2/ANKK1 Taq1A), COMT rs4680, and DBH rs1611115 was done at Stage 2.
Results and discussion. The ADR and non-ADR groups showed no statistically significant differences in the daily dose of LEV in both children (696.1 and 500.0 mg/day, respectively; p=0.087) and adults (750.9 and 750.9 mg/day, respectively; p=0.13). The similar data were obtained for blood LEV concentrations in children (31.6 and 27.3 μg/ml, p=0.12) and in adults (23.1 and 17.6 μg/ml, respectively; p=0.12). There was a statistically significant association between the carriage of the heterozygous CT genotype of SNV rs1611115 and the rate of both behavioral (OR, 3.38; 95% CI, 1.25–9.14; p=0.042) and CNS ADRs in general (OR, 3.29; 95% CI, 1.29–8.44; p=0.036). Higher impulsivity values were recorded in the carriers of the CT + TT genotypes of SNV rs1800497 (p<0.05) and rs1611115 (p<0.01) compared with those of the CC genotype. No statistically significant intergroup differences were obtained for SNV COMP rs4680.
Conclusion. The dose-dependent effect of behavioral ADRs is absent in both pediatric and adult patients taking LEV. Increased impulsiveness in epileptic patients taking LEV is associated with the carriage of SNV rs1800497 and rs1611115. The LEV-induced behavioral ADRs are related to SNV DBH rs1611115 that can be considered as one of the potential genetic predictors for behavioral ADRs and impulsivity.

1. Helmstaedter C, Mihov Y, Toliat MR, et al. Genetic variation in dopaminergic activity is associated with the risk for psychiatric side effects of levetiracetam. Epilepsia. 2013; 54(1):36-44. doi: 10.1111/j.1528-1167.2012.03603.x

2. Karlov VA, Vlasov PN, Zhidkova IA. An open-label prospective clinical study of the efficacy and tolerability of brand-name and generic levetiracetam in the monotherapy of focal epilepsy in adults. Nevrologiya, neiropsikhiatriya, psikhosomatika = Neurology, Neuropsychiatry, Psychosomatics. 2018; (Special Issue 1):12-17 (In Russ.) doi: 10.14412/2074-2711-2018-1S-12-17

3. Deshpande LS, DeLorenzo RJ. Mechanisms of Levetiracetam in the control of status epilepticus and epilepsy. Front Neurol. 2014; 5(11): 1-5. doi:10.3389/fneur.2014.00011

4. Bochanova EN, Shnayder NA, Dmitrenko DV. Comparative evaluation of the frequency of aggravation of epileptic seizures against the background of the use of antiepileptic drugs of various generations. Farmateka = Pharmateca. 2017; 9:56-60 (In Russ.)

5. Bochanova EN, Shnayder NA, Zyryanov SK, et al . Age-related and genderrelated aspects of adverse side effects in patients with epilepsy and epileptic syndromes (according to the University clinic register). Farmateka = Pharmateca. 2016; 7:71-75 (In Russ.)

6. Craig I, Halton K. Genetics of human aggressive behavior. Hum Genet. 2009; 126: 101-113. doi: 10.3389/fneur.2018.00905

7. Gong P, Liu J, Li S, et al. Dopamine betahydroxylase gene modulates individuals’ empathic ability. Social Cognitive and Affective Neuroscience. 2014; 9(9):1341-5. doi: 10.1093/scan/nst122

8. Stelzel C, Basten U, Montag C, et al. Frontostriatal involvement in task switching depends on genetic differences in d2 receptor density. J Neurosci. 2010; 30:14205-12. doi: 10.1523/JNEUROSCI.1062-10.2010

9. Savitz J, Hodgkinson CA, Martin-Soelch C, et al. DRD2/ANKK1 Taq1A polymorphism (rs1800497) has opposing effects on D2/3 receptor binding in healthy controls and patients with major depressive disorder. Int J Neuropsychopharmacol. 2013; 16(9):2095-101. doi:10.1017/S146114571300045X

10. Tsirkin VI, Bagaev VI, Bein BN. Role of dopamine in brain activity (literature review). Vyatskiy Meditsinskiy Vestnik = Vyatka Medical Herald. 2010; 1:7-18 (In Russ.)

11. Arias-Carrion O, Stamelou M, MurilloRodriguez E, et al. Dopaminergic reward system: a short integrative review. International Archives of Medicine. 2010; 3(24):1-6. doi:10.1186/1755-7682-3-24

12. Brodie MJ, Besag F, Ettinger AB, et al. Epilepsy, antiepileptic drugs, and aggression: an evidence-based review. Pharmacol Rev. 2016; 68:563-602. doi: 10.1124/pr.115.012021

13. Bozzi Yu, Borrelli E. The role of dopamine signaling in epileptogenesis. Frontiers in cellular neuroscience. 2013; 7:157. doi: 10.3389/fncell.2013.00157

14. Hess C, Reif A, Strobel A, et al. A functional dopamine-beta-hydroxylase gene promoter polymorphism is associated with impulsive personality styles, but not with affective disorders. J Neural Transm. 2009; 116(2): 121-30. doi: 10.1007/s00702-008-0138-0

15. Anokhina IP, Veretinskaya AG, Kuznetsova MN, et al. Dopamine-beta-hydroxylase activity and 1021 C/T polymorphism of its gene in patients with alcoholism. Voprosy narkologii = Substance Abuse Issues. 2009; 4:57-65 (In Russ.)

16. Shklovsky VM, Vilyanov VB, Remennik AYu, et al. Interaction between rs1800497 ANKK1 and rs2075654 DRD2 polymorphisms in patients with ischemic and hemorrhagic stroke. Vestnik vosstanovitelnoy meditsini = Bulletin of restorative medicine. 2014; 3:117-118 (In Russ.)

17. Wakita M, Kotani N, Kogure K, et al. Inhibition of excitatory synaptic trans-mission in hippocampal neurons by Levetiracetam involves Zn2+-dependent GABAA receptormediated presynaptic modulation. J Pharmacol Exp Ther. 2014; 348(2):246–59. doi:10.1124/jpet.113.208751

18. Fukuyama K, Tanahashi S, Nakagawa M, et al. Levetiracetam inhibits neurotransmitter release associated with CICR. Neurosci Lett. 2012; 518:69–74. doi:10.1016/j.neulet.2012.03.056

19. Du H, Nie S, Chen G, et al. Levetiracetam ameliorates L-DOPA-induced dyskinesia in hemiparkinsonian rats inducing critical molecular changes in the striatum. Parkinson’s Dis. 2015; 2015:253878. doi: 10.1155/2015/253878